Correction to: Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-022-00970-8, published online 27 May 2022
In this article, the funding from “National Natural Science Foundation of China to YR (Grant# 82125034), National Key R&D Program of China (#2020YFE0202200, #2021YFA1300200).” was omitted.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhong, T., Sun, X., Yu, L. et al. Correction: PROTAC mediated FKBP12 degradation enhances Hepcidin expression via BMP signaling without immunosuppression activity. Sig Transduct Target Ther 7, 197 (2022). https://doi.org/10.1038/s41392-022-01051-6
Published:
DOI: https://doi.org/10.1038/s41392-022-01051-6
